NanoViricides, Inc. (NNVC)
| Market Cap | 26.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.12M |
| Shares Out | 11.53M |
| EPS (ttm) | -0.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,120 |
| Open | 2.55 |
| Previous Close | 2.55 |
| Day's Range | 2.25 - 2.55 |
| 52-Week Range | 2.25 - 8.71 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 8.75 (+280.4%) |
| Earnings Date | n/a |
About NNVC
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-In...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NanoViricides stock is "Strong Buy" and the 12-month stock price forecast is 8.75.
News
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug...
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanome...
EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment
NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the form...
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-...
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicine...
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021 ...
NanoViricides: There Is More to Come
NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from the...
NanoViricides COVID-19 Treatment Candidate Found Effective Against Coronavirus Variants In Lab Study
Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID-19 ...
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstra...
Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstra...
SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19. The good news is they suc...
NanoViricides: Why Has the Stock Doubled?
There were a large number of pharma companies of all sizes that began their research on developing both drugs as well as vaccines to counter the SARS-CoV-2 since 2019. Some of these companies have succe...
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Dru...
SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin...
NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?
A Covid-19 treatment producer halted trading this morning, but news has revealed that NNVC stock is still moving upward. The post NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?
Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern
Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tuesday following news of the company reporting significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thu...
What Is a ‘News Pending' Halt? What to Know as NNVC Stock Captivates Investors
Today, NanoViricides is grabbing a lot of attention due to a news pending halt that has sent NNVC stock skyrocketing. The post What Is a ‘News Pending' Halt?
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
SHELTON, Conn., Sept. 14, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE Amer.
NanoViricides Review: What you Need to Know About the Company
With the coronavirus changing the world in 2020, it makes sense that there's a spotlight on science to prevent viruses from growing into pandemics. While Pfizer (NYSE: PFE) and Moderna Inc. (NASDAQ: MRN...
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Can...
SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicin...
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in S...
SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines ...
NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies
Shares of nano-cap biopharma NanoViricides, Inc. (NASDQ: NNVC) were trading solidly higher Tuesday following a positive data readout. What Happened: Two NanoViricides COVID-19 clinical drug candidates —...
NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today
NanoViricides (NNVC) stock is on the rise Tuesday after revealing results from the company's drug candidates to treat the coronavirus. The post NNVC Stock: The COVID-19 Drug News That Has NanoViricides ...
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pr...
SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine tech...
NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19
NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections. The treatment candidate was well toler...
Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy
New York, New York--(Newsfile Corp. - November 18, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a...
NanoViricides: One Step at a Time
As the confirmed Covid-19 death toll nears the 1.3 million mark, pharma and biotech companies all over the world are making progress in their attempts to develop a cure for the disease.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NanoViricides, Inc. and Encoura...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or “the Company”) (NYSE: NNVC...